A number of original studies that investigated the clinical and prognostic significance of MCT4 have been conducted in various types of cancers, such as lung cancer, prostate cancer, and colorectal cancer [23–27], suggesting a functional role of the MCT4 in tumor progression. Here, SLC16A3 is linked to prostate carcinoma.